Vivo Bio Tech Valuation

Is 511509 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 511509 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 511509's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 511509's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 511509?

Key metric: As 511509 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 511509. This is calculated by dividing 511509's market cap by their current earnings.
What is 511509's PE Ratio?
PE Ratio	7.6x
Earnings	₹74.57m
Market Cap	₹595.84m

511509 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.3x
Enterprise Value/EBITDA	4.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 511509's PE Ratio compare to its peers?

The above table shows the PE ratio for 511509 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	45.1x
544184 Borosil Scientific	56.1x	n/a	₹16.1b
524394 Vimta Labs	34.4x	n/a	₹16.5b
TARSONS Tarsons Products	58.5x	27.7%	₹20.9b
WINDLAS Windlas Biotech	31.6x	n/a	₹20.0b
511509 Vivo Bio Tech	7.6x	n/a	₹595.8m

Price-To-Earnings vs Peers: 511509 is good value based on its Price-To-Earnings Ratio (7.6x) compared to the peer average (45.1x).

Price to Earnings Ratio vs Industry

How does 511509's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 511509 is good value based on its Price-To-Earnings Ratio (7.6x) compared to the Asian Life Sciences industry average (30.7x).

Price to Earnings Ratio vs Fair Ratio

What is 511509's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

511509 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	7.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 511509's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Caplin Point Laboratories

₹148.3b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,952.15

-0.09%

60.0%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

14.0%

21.4%

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

-4.9%

6.1%